



OPEN

Standardization procedure for flow cytometry data harmonization in prospective multicenter studies

Lucas Le Lann¹, Pierre-Emmanuel Jouve², Marta Alarcón-Riquelme³, Christophe Jamin^{1,4}✉, Jacques-Olivier Pers¹, PRECISESADS Flow Cytometry Study Group* & PRECISESADS Clinical Consortium*

One of the most challenging objective for clinical cytometry in prospective multicenter immunomonitoring trials is to compare frequencies, absolute numbers of leukocyte populations and further the mean fluorescence intensities of cell markers, especially when the data are generated from different instruments. Here, we describe an innovative standardization workflow to compare all data to carry out any large-scale, prospective multicentric flow cytometry analysis whatever the duration, the number or type of instruments required for the realization of such projects.

One of the challenges not yet fully resolved for clinical cytometry¹ is to compare, in prospective multicenter immunomonitoring trials, the frequencies and absolute values of various leukocyte populations, especially if the data are generated from different instruments and from different companies. The problem is even more difficult when it comes to comparing the expression of the markers² on freshly collected sample to avoid alteration of expression following freezing processes³. If the fluorescence variations between different antibody lots remain a major problem, the divergent results can be seen as a result of inappropriate gating strategies between the centers⁴ or because of imperfect fluorescence compensation^{5,6}.

Recently, several studies have sought to move this issue forward without being able to meet all the criteria. Some have chosen to use equipment mainly from the same manufacturer^{7,8}, others have preferred frozen samples^{3,9} or have resigned themselves to not doing prospective studies¹⁰, while others have carried out inter-instrument comparability studies but on few samples¹¹.

As part of the IMI PRECISESADS study project, a multicenter analysis, using eleven different instruments (Navios, Gallios from Beckman Coulter, Canto II, Fortessa, Verse, Aria from BD Biosciences), prospectively on blood freshly collected from 2,559 individuals over a period of 4 years, was required. The objective was to compare the distribution (frequencies and absolute values) of leukocyte populations and the mean fluorescence intensities (MFIs) of the markers of the studied populations in order to establish a new classification of autoimmune diseases in relation to all the "omic" collection of data. We have preliminarily developed and published a standard operating procedure (SOP) for the standardization of all instruments based on VersaComp Capture beads (Beckman Coulter) for inter-center harmonization. The objective was to establish the settings of each instrument leading to the generation of similar MFIs when acquiring identical samples. A second SOP was also developed using 8 peak beads (Beckman Coulter) for the intra-center daily QC to preserve intra-instrument stability over the project period. Overall, these different SOPs were followed by all centers with the aim of obtaining inter-instrument coefficients of variation (CVs) of less than 5%¹². The relevance of this approach was demonstrated by an analysis of the same sample of control blood which highlighted a similar sensitivity of all devices in terms of frequencies of populations studied but also in terms of MFI markers studied¹².

¹INSERM, UMR1227, CHRU Morvan, Lymphocytes B et Autoimmunité, Univ Brest, BP 824, 29609 Brest, France. ²Altrabio SAS, Lyon, France. ³GENYO, Centre for Genomics and Oncological Research Pfizer, University of Granada, Andalusian Regional Government, PTS Granada, Granada, Spain. ⁴Laboratoire d'Immunologie et Immunothérapie, CHU de Brest, Brest, France. *Lists of authors and their affiliations appear at the end of the paper. ✉email: christophe.jamin@univ-brest.fr




Figure 1. Workflow of the standardization procedure for the harmonization of flow cytometry data in multicentric prospective studies. Flow cytometers are firstly harmonized using VersaComp capture beads to achieve the same reference for all instruments (step 1). For the acquisition of blood samples, 8 peak beads are used as daily quality control. A R script allows the normalization of the data for each instrument to the reference during the period of inclusions (step 2). The compensation of all flow cytometry files are verified and adjusted to minimize disparities in the data file preparation (step 3). Frequencies of the populations of interest and the mean fluorescence intensities of the cell surface markers are automatically collected from all flow cytometry files by automaton having learned the gating strategy through machine learning (step 4). The mean fluorescence intensities of the cell surface markers are corrected by a Python script to adjust the median values and eliminate antibody batches variations in each instrument (step 5). The mean fluorescence intensities are finally corrected by an additional python script to correct the variations of the median values between the instruments (step 6).

Harmonization of the instruments

The effective harmonization of the instruments through this procedure (Fig. 1, step 1) enables the realization of the large-scale multicentric phenotypic analyzes and assumes the stability of the 11 instruments throughout the duration of the study. Immunomonitoring of the individuals included in the PRECISESADS study was performed using 2 DuraClone antibody panels (Beckman Coulter) dedicated to the analysis of various populations of leukocytes and mononuclear cells in the peripheral blood (Supplementary Table 1). Despite the preliminary precautions taken upstream¹², the development of a supplementary standardization was necessary to harmonize the flow cytometry data. Different steps have been identified for this procedure and are described in the current manuscript.

Intra-center normalization

Initially, a first R script was developed to normalize the results over the 4-year period for each single center based on the targets of the initial harmonization in order to correct variations potentially observed in the daily QC (Supplementary Document 1). The different steps are: 1. Loading of the packages flowCore, flowStats, flowViz, ggcyt; 2. Function to revise channel name position and standard names when necessary; 3. Function to extract the MFI of the 8 peak beads files with identification of Beckman Coulter and BD Biosciences files, identification of files containing debris; 4. Function to define the alpha and beta transformation parameters that will be used to normalize the FCS files; 5. Application of the normalization function using a linear regression with the determined alpha and beta parameters and using as a reference the MFI of the 8 peak beads obtained during

the initial calibration procedure for the harmonization of the instruments; 6. Verification of the effect in all channels. In order to validate this script, we performed an additional experiment. We voluntarily modified the PMTs of a Navios to provoke a measurement variation of the MFIs of the order of 10 to 15% on the 8 peak beads (Supplementary Figure 1a and Supplementary Table 2). As a result, these changes were made in the MFIs of the membrane markers studied during the acquisition of a blood test sample with DuraClone Panel 1 (Supplementary Figure 1b and Supplementary Table 3). The application of the R script on the LMD files of the 8 peak beads makes its MFI correspond to those obtained without modification of the PMTs, with coefficients of variation lower than 2.5% (Supplementary Figure 1c and Supplementary Table 2). Executed on the LMD files of the blood test sample stained with DuraClone Panel 1, the script also allowed MFIs of the membrane markers corresponding to the MFIs obtained without PMT modification, with coefficients of variation of less than 5% (Supplementary Figure 1d and Supplementary Table 3). Thus, this R script makes it possible to standardize the results generated by the machine (Fig. 1, step 2) and ensures the stability of its data throughout the duration of the project. This standardization R script also enables the comparability of the results between the centers, as demonstrated by the analysis of the immunomonitoring of the same blood control stained with the DuraClone panel 1, carried out after the 4 years. The results show frequency variation coefficients measured between centers ranging from 2.3% for neutrophils to 17.7% for monocytes, and MFI variation coefficients ranging from 10.9% for the CD3 molecule to 30.9% for the CD15 molecule (Supplementary Figure 2), confirming the stability of all instrument mirroring, performed as a prerequisite before starting the inclusions¹², over the entire study period¹².

“Manual” compensation of the flow cytometry data files

The inclusion of the study's 2,559 individuals was done along the way during the 4 years of the PRECISESADS project between December 2014 and December 2018. All FCS and LMD files from the acquisition of samples labeled with DuraClone Panel 1 and DuraClone Panel 2 were standardized with the R script. Then, the standardized file compensation matrices were verified and adjusted when necessary. This step was completed by the same single operator using Kaluza[®] software (Beckman Coulter) to minimize file preparation variations (Fig. 1, step 3). Values at the beginning (December 2014) and at the end of the inclusions (December 2018) have been compared and found statistically reproducible (not shown).

Automated gating of the compensated files

Being extremely time-consuming, the “manual” compensation adjustments were followed by a procedure dedicated to the automated (algorithm based) gating of the FCS files, in order to gather information on frequency and absolute number of the cell populations as well as their MFI for the studied markers. Several automated gating algorithms have been able to achieve similar results to the centralized manual gating analysis for public datasets and have shown the advantages of consistency and reproducibility¹³. There are a number of software packages available for automatic analysis by multiple algorithms such as dimensionality reduction¹⁴, mixture model-based clustering¹⁵, artificial neural network¹⁶, density based clustering¹⁷... Approximately, there are two broad categories of automated flow cytometry data analysis approaches. The supervised methods which are suitable for mimicking manual gating process for predetermined cell populations and the unsupervised strategies which can identify cell populations with minimal user input, and are notably appropriate for biomarker discovery^{18,19}. For this current study, in order to address the need of an efficient, consistent and robust analysis of large scale, multi-parameter flow cytometry datasets from multiple immunomonitoring panels in 11 different centers, we have developed, validated and applied robust and reproducible automated pipelines that replicates manual analysis. The automation of gating has been built using a supervised Machine Learning based approach using training datasets gated manually. Some unique approaches have been adopted to leverage data pre-processing, feature engineering, transfer learning and data augmentation to overcome the major challenges encountered in building predictive models for cytometry data automated gating²⁰. This automation requires a two steps workflow. A first step customized for each instrument due to potential strong differences in signal for the Forward Scatter and Side Scatter (FS / SS) measures across cytometers (Supplementary Figure 3a and 3b). A second non instrument specific step, for gating remaining populations of interest (Supplementary Figure 3c and 3d). In order to validate the Machine Learning based algorithms for panel 1 and panel 2 (these algorithms are hereafter name automatons), we carried out additional intermediate evaluations. We compared the results of the automatons with a traditional “manual” analysis performed with the Kaluza[®] software, on 300 patients distributed throughout the 11 centers. The comparison of the results shows a very good correlation of the data of frequencies, absolute values and the MFIs (Supplementary Figure 4a–c), making it possible to validate the efficiency of the automatons (Fig. 1, step 4). The flow cytometry data (frequencies, absolute values, and MFIs) of the 2,559 individuals included throughout the 4 years of the study are being extracted automatically by the automatons. A principal component analysis (PCA) of these data shows homogeneity of results between centers on frequencies (Fig. 2a) but disparities between centers on MFIs (Fig. 2b). What was not observed in analyses of a small number of samples (reference¹² and Supplementary Figure 2) has been unveiled with the data from the whole cohort.

Intra-center correction of the data

We, therefore, sought which parameter(s) could be responsible for these “center effects” despite the initial harmonization of the 11 cytometers and the intra-center normalization of each instrument to circumvent these dispersions.

First, the monoclonal antibodies chosen for immunomonitoring are used in DuraClone (Beckman Coulter) format. This dried antibody formulation provides stability over time, ease of storage, and avoids pipetting errors during sample preparation²¹. However, three different lots were used during the 4 years of the study. The MFI analysis of each panel 1 (Supplementary Figure 5a–d) and panel 2 (Supplementary Figure 5e–g) markers shows




Figure 2. Evolution of principal component analysis during the workflow of the standardization procedure of flow cytometry data in multicentric prospective studies. Peripheral blood of 2,559 individuals was labeled with the dry panel 1 and panel 2 antibody formulations and then analyzed by flow cytometry using 11 different, previously harmonized instruments. The data of each instrument was then standardized by the R script. The frequencies of the leukocyte populations (panel 1) and mononuclear cells (panel 2) (a) and the mean fluorescence intensities of the cell surface markers (b) were collected from all flow cytometry files by automaton having learned the gating strategy through machine learning and were analyzed by principal component analysis (PCA). The mean fluorescence intensities of the cell surface markers were corrected by a Python script to adjust the median values and eliminate antibody batches variations in each instrument, before being analyzed by PCA (c). The mean fluorescence intensities were finally corrected by an additional Python script to eliminate the variations of the median values between the instruments, before being analyzed by PCA (d).

variations in batch changes. Therefore, we elaborated a new script under Python to correct the data between batches for each of the 11 instruments including also the variations observed after the 7 calibration procedures¹² repeated during the 4-year inclusion (see the “Methods” section, and Supplementary Document 2). The different steps are: 1. Importation of the useful modules (os.path, glob, os, matplotlib.pyplot, matplotlib.colorbar, numpy, pandas, csv, re); 2. Extraction of all the data from the FCS files of a patient ID with search of the acquisition dates of the patient ID; 3. Determination of the coefficient for the correction of the batch effect; 4. Computation of the coefficient for each batch and application to the MFI of each channel and saving in a new csv file. Briefly, a coefficient for each batch is calculated by dividing the MFI of all samples of the first batch by the MFI of all samples of each subsequent batch. Then the MFI of each sample is corrected using these coefficients. Based on the alignment of the median values of the different batches with those of the first batch used for each center (Fig. 1, step 5), the variations of the MFIs over time for each of the markers studied disappeared after application of the Python script (Supplementary Figure 5a–g). Nevertheless, despite this correction, the PCA evaluation of the distribution of MFIs between instruments showed a persistent “center effect” (Fig. 2c).

Inter-center correction of the data

Intrinsic variations in the optical bench of each instrument remained and lead to measurement disparities in MFIs that are dependent on the target of the antibodies used and the associated fluorochromes⁸. Assuming that the number of individuals included is different from one center to another (Supplementary Figure 6a) but that all centers included all the variety of patients (Supplementary Figure 6b) and that the inclusions of the type of individuals were heterogeneous throughout the 4-year period in all centers (Supplementary Figure 6c), the medians of the MFIs on all measures must be equivalent regardless of the center. We therefore developed an additional Python script (Supplementary Document 3) to correct the medians of the MFIs of each marker between all the instruments (Fig. 1, step 6), using the same Navios cytometer as a reference for all other machines throughout the project¹². The different steps are: 1. Importation of the useful packages (os.path, glob, os, numpy, re, subprocess); 2. Extraction of the coefficient for the different cytometers used by each center; 3. Computation of the coefficient of each instrument and application of each coefficient to the MFI of all channels saved in a new csv file. Briefly, a coefficient for each channel is calculated by dividing the MFI of all samples of the reference center by the MFI of all samples of all subsequent center. Then the MFI of each sample is corrected using these coefficients. After applying this script, the median values of each marker became insignificantly different regardless of the instrument with which the measurements were made (Supplementary Figure 7a,b). A new PCA showed homogeneous distribution of MFIs for all the markers studied in panel 1 as well as in panel 2 (Fig. 2d). Yet, individual variations specific of each patient are still maintained. As an example, the CD19 MFI variations observed between

diseases in all centers persist after application of the script pipeline (Supplementary Figure 7c). Importantly, this indicates that the harmonization procedure, while correcting the instrument differences, preserves the biological differences between individuals.

Finally, the implementation of the workflow described in Fig. 1 made it possible to compare all the data of frequencies, absolute values and MFIs resulting from the data generated by the immunomonitoring of 2,559 individuals included over a period of 4 years by 11 different flow cytometers. Biostatistical analyses including these flow cytometry data with the set of "omic" data collected as part of the PRECISESADS project are now possible. More broadly, with all the validity required to follow the elaborated standardization procedures, this new workflow opens the possibility of carrying out any large-scale, prospective multicentric flow cytometry analysis whatever the duration, number and type of instruments required for the realization of such projects.

Methods

Participant recruitment. The PRECISESADS study is a European multi-center, non-randomized, and observational clinical study with recruitment performed between December 2014 and December 2018 at 19 institutions in 9 countries (Austria, Belgium, France, Germany, Hungary, Italy, Portugal, Spain and Switzerland). The study had two types of patient recruitment that included a cross-sectional study and an inception prospective study with patients followed at two time points, registered with number NCT02890121 and NCT02890134 in ClinicalTrials.gov, respectively. The target number of included patients affected by systemic autoimmune diseases was 2005 (around 400 by disease or group of diseases: rheumatoid arthritis, scleroderma or systemic sclerosis, primary Sjögren's syndrome, systemic lupus erythematosus, and primary antiphospholipid syndrome, mixed connective tissue disease and undifferentiated connective tissue disease) and 554 healthy controls. An ethical protocol was prepared, reached consensus across all partners, academic and industrial, translated into all participant's languages and approved by each of the local ethical committees of the clinical recruitment centers, and all experimental protocols were approved by each of the local committees:

- Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Comitato Etico Italy.
- Centre Hospitalier Universitaire de Brest, Hospital de la Cavale Blanche, Avenue Tanguy Prigent 29,609, Brest, France. Comité de Protection des Personnes Ouest VI.
- Pôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium. Comité d'Éthique Hospitalo-Facultaire.
- Centro Hospitalar do Porto, Portugal. Comissão de ética para a Saúde – CES do CHP.
- Servicio Cantabro de Salud, Hospital Universitario Marqués de Valdecilla, Santander, Spain. Comité ético de investigación clínica de Cantabria. IDIVAL.
- Hospital Clinic I Provincia, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. Comité Ètica de Investigació Clínica del Hospital Clínic de Barcelona. HOSPITAL CLÍNIC DE BARCELONA.
- Katholieke Universiteit Leuven, Belgium. Commissie Medische Ethiek UZ KU Leuven /Onderzoek.
- Klinikum der Universität zu Köln, Cologne, Germany. Geschäftsstelle Ethikkommission
- Medizinische Hochschule Hannover, Germany. Ethikkommission.
- Medical University Vienna, Vienna, Austria. Ethik Kommission. Borschkegasse.
- Servicio Andaluz de Salud, Hospital Universitario Reina Sofía Córdoba, Spain. Comité de Ética e la Investigación de Centro de Granada (CEI – Granada).
- Servicio Andaluz de Salud, Complejo hospitalario Universitario de Granada (Hospital Universitario San Cecilio), Spain. Comité de Ética e la Investigación de Centro de Granada (CEI – Granada).
- Servicio Andaluz de Salud, Complejo hospitalario Universitario de Granada (Hospital Virgen de las Nieves), Spain. Comité de Ética e la Investigación de Centro de Granada (CEI – Granada).
- Servicio Andaluz de Salud, Hospital Regional Universitario de Málaga, Spain. Comité de Ética e la Investigación de Centro de Granada (CEI – Granada).
- Università degli studi di Milano, Milan, Italy. Policlinico di Milano, Comitato Etico Italy.
- Hôpitaux Universitaires de Genève, Switzerland. DEAS –Commission Cantonale d'Éthique de la recherche Hôpitaux universitaires de Genève.
- University of Szeged, Szeged, Hungary. Csongrad Megyei Kormányhivatal.
- Charité, Berlin, Germany. Ethikkommission.
- Andalusian Public Health System Biobank, Granada, Spain.
- Comité de Ética e la Investigación de Centro de Granada (CEI – Granada).

All patients recruited to the study were aged 18 years or older and signed an informed consent form, and all methods were carried out in accordance with relevant guidelines and regulations. The study adhered to the standards set by International Conference on Harmonization and Good Clinical Practice, and to the ethical principles that have their origin in the Declaration of Helsinki (2013). The protection of the confidentiality of records that could identify the included individuals is ensured as defined by the EU Directive 2001/20/EC and the applicable national and international requirements relating to data protection in each participating country.

The immunophenotyping of the individuals were performed by flow cytometry using 2 DuraClone antibody panels (Beckman Coulter) dedicated to the analysis of various populations of leukocytes and mononuclear cells in the peripheral blood of individuals (Supplementary Table 1). Absolute numbers using Flow Count fluorospheres (Beckman Coulter), frequencies of the different cell populations and MFIs of the cell surface markers were collected: CD3+CD19- T cells, CD3+CD4+CD8- T cells, CD3+CD4-CD8+ T cells, CD3-CD19+ B cells, CD3-CD56+ NK cells, CD3-CD56highCD16low NK cells, CD3-CD56lowCD16high NK cells CD3+CD56+ NK-like T

cells, CD4lowCD14+CD16- classic monocytes, CD4lowCD14+ CD16+ intermediate monocytes, CD4lowCD14-CD16+ non-classic monocytes, CD15+CD16low eosinophils, and CD15+CD16high neutrophils with panel 1 (Supplementary Figure 3c); HLA-DR-CD123+ basophils, HLA-DR+Lin-CD123+CD11c- pDC, HLA-DR+ Lin-CD123-CD11c+ mDC, HLA-DR+ Lin-CD123-CD11c+ CD1c+CD141- mDC1 and HLA-DR+Lin-CD123-CD11c-CD141+ mDC2 with panel 2 (Supplementary Figure 3d).

Furthermore, to reduce the variability that may occur during the sample preparations, all centers received the same SOP explaining how to prepare the lysis buffer, to handle the required volume of blood samples and rehydrate the antibodies in the DuraClone tubes, to add FlowCount fluorospheres (Beckman Coulter) for the absolute number calculation and finally how to prepare the instruments on a daily basis with the acquisition of Rainbow 8-peak beads (Beckman Coulter). These standardize procedure have been followed by all users in all centers to minimize technical bias.

Flow cytometry acquisition was managed at each center after a multi-center harmonization of flow cytometers to ensure mirroring of all instruments, thereby allowing subsequent integration of all the data obtained across the different sites and instruments, as previously described¹². Briefly, one flow cytometer (NAVIOS-1) was chosen as reference instrument and fixed the mean fluorescence intensities (MFIs) of 8 different fluorochrome conjugated antibodies using VersaComp Ab capture beads (Beckman Coulter). The ten other instruments adjusted their own PMT voltages to reach the same MFIs. These values constituted their initial reference settings. Furthermore, to evaluate the fluctuation of the instruments overtime and to minimize deviation, this standardization procedure was repeated every 3 to 6 months. If required, PMT voltages were adjusted to maintain identical MFI values of the target fluorescence intensities. In that case, the PMT values were set in the 2 multiparameter panels serving as new intra-instrument reference assessments for the inclusion of future individual samples. Subsequently to the standardization of all instruments, each center used Rainbow 8-peak beads (Beckman Coulter) on a daily basis to follow the stability of their instrument overtime. The deviation of the MFI values of the peaks of every fluorochrome must be < 5% compared to the internal reference. In cases where instrument performance failed, while cleaning, de-gassing flow cell and laser delay were verified, PMT values were modified to adjust the position of the fluorescence peaks in their initial positions. Revised PMTs were then reported in the 2 panels of the immunophenotyping. Compensation matrices that could be impacted were adjusted later during the analysis procedure.

Moreover, to facilitate the elaboration of the scripts able to read LMD files generated by Beckman Coulter instruments as well as FCS files generated by BD Biosciences instruments, all centers received SOPs before starting the inclusions of samples to generate consistent instrument files. These SOPs were dedicated to the preparation of the flow cytometers (namely the protocols for the Beckman Coulter instruments and the sheets for the BD instruments), including uniform specific name of the different parameters (forward scatter and side scatter settings, fluorochrome designation), identical stop count or time of acquisition, and uniform labelling of the LMD and FCS files. Despite all these precautions, errors have been detected for some files. The script codes have thus been modified and implemented to detect and correct these errors in order to avoid the exclusion of the corresponding samples from the overall analyses (Supplementary Documents).

Received: 5 September 2019; Accepted: 22 June 2020

Published online: 14 July 2020

References

- Pedreira, C. E. *et al.* Overview of clinical flow cytometry data analysis: recent advances and future challenges. *Trends Biotechnol.* **31**, 415–425. <https://doi.org/10.1016/j.tibtech.2013.04.008> (2013).
- Bottcher, S. *et al.* Lot-to-lot stability of antibody reagents for flow cytometry. *J. Immunol. Methods.* <https://doi.org/10.1016/j.jim.2017.03.018> (2017).
- Iverson, S. *et al.* A standardized immune phenotyping and automated data analysis platform for multicenter biomarker studies. *JCI Insight.* <https://doi.org/10.1172/jci.insight.121867> (2018).
- Finak, G. *et al.* Standardizing flow cytometry immunophenotyping analysis from the human immunophenotyping consortium. *Sci. Rep.* **6**, 20686. <https://doi.org/10.1038/srep20686> (2016).
- Kalina, T. *et al.* Quality assessment program for EuroFlow protocols: summary results of four-year (2010–2013) quality assurance rounds. *Cytometry A* **87**, 145–156. <https://doi.org/10.1002/cyto.a.22581> (2015).
- Kalina, T. *et al.* Frequent issues and lessons learned from EuroFlow QA. *J. Immunol. Methods.* <https://doi.org/10.1016/j.jim.2018.09.008> (2018).
- Streitz, M. *et al.* Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE study. *Transplant. Res.* **2**, 17. <https://doi.org/10.1186/2047-1440-2-17> (2013).
- Kalina, T. *et al.* EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. *Leukemia* **26**, 1986–2010. <https://doi.org/10.1038/leu.2012.122> (2012).
- Veluchamy, J. P. *et al.* Standardized and flexible eight colour flow cytometry panels harmonized between different laboratories to study human NK cell phenotype and function. *Sci. Rep.* **7**, 43873. <https://doi.org/10.1038/srep43873> (2017).
- Solly, F. *et al.* Comparable flow cytometry data can be obtained with two types of instruments, Canto II, and Navios. A GEIL study. *Cytometry A* **83**, 1066–1072. <https://doi.org/10.1002/cyto.a.22404> (2013).
- Glier, H. *et al.* Standardization of 8-color flow cytometry across different flow cytometer instruments: a feasibility study in clinical laboratories in Switzerland. *J. Immunol. Methods.* <https://doi.org/10.1016/j.jim.2017.07.013> (2017).
- Jamin, C. *et al.* Multi-center harmonization of flow cytometers in the context of the European “PRECISESADS” project. *Autoimmun. Rev.* **15**, 1038–1045. <https://doi.org/10.1016/j.autrev.2016.07.034> (2016).
- Aghaepour, N. *et al.* Critical assessment of automated flow cytometry data analysis techniques. *Nat. Methods* **10**, 228–2238. <https://doi.org/10.1038/nmeth.2365> (2013).
- Amir, A. D. *et al.* viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. *Nat. Biotechnol.* **31**, 545–552. <https://doi.org/10.1038/nbt.2594> (2013).

15. Sorensen, T. *et al.* immunoClust—an automated analysis pipeline for the identification of immunophenotypic signatures in high-dimensional cytometric datasets. *Cytometry A* **87A**, 603–615. <https://doi.org/10.1002/cyto.a.22626> (2015).
16. Van Gassen, S. *et al.* FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data. *Cytometry A* **87**, 636–645. <https://doi.org/10.1002/cyto.a.22625> (2015).
17. Qian, Y. *et al.* Elucidation of seventeen human peripheral blood B-cell subsets and quantification of the tetanus response using a density-based method for the automated identification of cell populations in multidimensional flow cytometry data. *Cytometry B Clin. Cytom.* **78**, S69–82. <https://doi.org/10.1002/cyto.b.20554> (2010).
18. Mair, F. *et al.* The end of gating? An introduction to automated analysis of high dimensional cytometry data. *Eur. J. Immunol.* **46**, 34–43. <https://doi.org/10.1002/eji.201545774> (2016).
19. Conrad, V. K. *et al.* Implementation and validation of an automated flow cytometry analysis pipeline for human immune profiling. *Cytometry A* **95**, 183–191. <https://doi.org/10.1002/cyto.a.23664> (2019).
20. Lee, H. *et al.* High-throughput analysis of clinical flow cytometry data by automated gating. *Bioinform Biol Insights* **13**, 1177932219838851. <https://doi.org/10.1177/1177932219838851> (2019).
21. Hedley, B. D., Keeney, M., Popma, J. & Chin-Yee, I. Novel lymphocyte screening tube using dried monoclonal antibody reagents. *Cytometry B Clin. Cytom.* **88**, 361–370. <https://doi.org/10.1002/cyto.b.21251> (2015).

Acknowledgements

The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under the Grant Agreement Number 115565, resources of which are composed of financial contribution from the European Union's Seventh Framework Program (FP7/2007–2013) and EFPIA companies' in kind contribution. LLL was supported by the Agence Nationale de la Recherche under the “Investissement d’Avenir” program with the Reference ANR-11-LABX-0016-001 and the Région Bretagne.

Author contributions

L.L.L. developed the scripts and analyzed the flow cytometry files; C.J. and J.O.P. designed the work and wrote the manuscript; P.E.J. developed the automats for the Machine Learning; The PRECISESADS Clinical Consortium agreed on the clinical data, recruited the individuals, performed the clinical assessment and obtained the samples; L.L.L., C.J., J.O.P. and the PRECISESADS Flow Cytometry Study Group calibrated the flow cytometers across all recruitment centers, normalized and acquired the flow cytometry data; M.A.R. and J.O.P. participated to the design of the PRECISESADS study and oversaw the progress of the study.

Competing interests

M. H.-F. and J. M. are employees of UCB. A. B. and Z. M. are employees of BAYER Pharma. All other authors declare no competing financial and/or non-financial interests in relation to the work described.

Additional information

Supplementary information is available for this paper at <https://doi.org/10.1038/s41598-020-68468-3>.

Correspondence and requests for materials should be addressed to C.J.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2020

PRECISESADS Flow Cytometry Study Group

Montserrat Alvarez⁵, Damiana Alvarez-Errico⁶, Nancy Azevedo⁷, Nuria Barbarroja⁸, Anne Buttgerit⁹, Qingyu Cheng¹⁰, Carlo Chizzolini⁵, Jonathan Cremer¹¹, Aurélie De Groof¹², Ellen De Langhe¹³, Julie Ducreux¹², Aleksandra Dufour⁵, Velia Gerl¹⁰, Maria Hernandez-Fuentes¹⁴, Laleh Khodadadi¹⁰, Katja Kniesch¹⁵, Tianlu Li⁶, Chary Lopez-Pedraza⁸, Zuzanna Makowska⁹, Concepción Marañón³, Brian Muchmore³, Esmeralda Neves⁷, Bénédicte Rouvière¹, Quentin Simon¹, Elena Trombetta¹⁶, Nieves Varela³ & Torsten Witte¹⁵

⁵Immunology and Allergy, University Hospital and School of Medicine, Geneva, Switzerland. ⁶Chromatin and Disease Group, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain. ⁷Serviço de Imunologia EX-CICAP, Centro Hospitalar e Universitário do Porto, Porto, Portugal. ⁸IMIBIC, Reina Sofia Hospital, University of Cordoba, Córdoba, Spain. ⁹Bayer AG, Berlin, Germany. ¹⁰Department of Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany. ¹¹Laboratory of Clinical Immunology, Department of Microbiology

and Immunology, KU Leuven, Leuven, Belgium. ¹²Pôle de Pathologies Rhumatismales Inflammatoires et Systémiques, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium. ¹³Division of Rheumatology, University Hospitals Leuven and Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Belgium. ¹⁶Laboratorio di Analisi Chimico Cliniche e Microbiologia - Servizio di Citofluorimetria, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy.

PRECISESADS Clinical Consortium

Rocío Aguilar-Quesada¹⁷, Maria Angeles Aguirre-Zamorano¹⁸, Isabel Almeida¹⁹, Niklas Baerlecken¹⁵, Attila Balog²⁰, Doreen Belz²¹, Lorenzo Beretta²², Ricardo Blanco Alonso²³, Márta Bocskai²⁰, Mariana Brandão¹⁹, José Luis Callejas Rubio²⁴, Ana Campar¹⁹, Maria-Carmen Castro-Villegas¹⁸, Ricardo Cervera²⁵, Eduardo Collantes¹⁸, Divi Cornec²⁶, Alfonso Corrales Martínez²³, Magdolna Deák²⁰, Valérie Devauchelle-Pensec²⁶, Sonja Dulic²⁰, Alejandro Escudero-Contreras¹⁸, Gerard Espinosa²⁵, Raquel Faria¹⁹, Fátima Farinha¹⁹, María Concepción Fernández Roldán²⁴, Tania Gomes Anjos³, Miguel A. González-Gay²³, Falk Hiepe²⁷, Nicolas Hunzelmann²¹, Sandrine Jousse-Joulin²⁶, Gabriella Kádár²⁰, Laszlo Kovács²⁰, Bernard Lauwerys²⁸, Michaela Lehner²⁹, Antonio López-Berrio¹⁷, Rik Lories³⁰, António Marinho¹⁹, Jacqueline Marovac¹⁴, Pier Luigi Meroni³¹, Blanca Miranda¹⁷, Immaculada Jiménez Moleón²⁴, Héctor Navarro-Linares¹⁷, Rafaela Ortega-Castro¹⁸, Norberto Ortego²⁴, Enrique Ramón Garrido³², Enrique Raya²⁴, Raquel Ríos Fernández²⁴, Ignasi Rodríguez-Pintó²⁵, Alain Saraux²⁶, Georg Stummvoll²⁹, Carlos Vasconcelos¹⁹ & Michael Zauner²⁹

¹⁴UCB, Slough, UK. ¹⁵Klinik für Immunologie Und Rheumatologie, Medical University Hannover, Hannover, Germany. ¹⁷Andalusian Public Health System Biobank, PTS Granada, Granada, Spain. ¹⁸Hospital Universitario Reina Sofía Andaluz de Salud, Córdoba, Spain. ¹⁹Centro Hospitalar do Porto, Porto, Portugal. ²⁰University of Szeged, Szeged, Hungary. ²¹Klinikum Der Universitaet Zu Koeln, Cologne, Germany. ²²Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan, Italy. ²³Hospital Universitario Marqués de Valdecilla, Servicio Cántabro de Salud, Santander, Spain. ²⁴Hospital Universitario San Cecilio, Servicio Andaluz de Salud, Granada, Spain. ²⁵Hospital Clinic I Provincia, Institut D'Investigacions Biomèdiques August Pi I Sunyer, Barcelona, Spain. ²⁶Centre Hospitalier Universitaire de Brest, Hopital de La Cavale Blanche, Brest, France. ²⁷Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany. ²⁸Université Catholique de Louvain, Louvain, Belgium. ²⁹Medizinische Universität Wien, Vienna, Austria. ³⁰Katholieke Universiteit Leuven, Leuven, Belgium. ³¹Università Degli Studi di Milano, Milan, Italy. ³²Hospital Regional de Málaga, Servicio Andaluz de Salud, Málaga, Spain.